Relationship between serum thyroid hormone and IL-1β levels and postmortem tissue deiodinase activity in critically ill patients
Abstract
Objective: This study investigated the relationship between serum thyroid hormones and IL-1β levels and postmortem tissue deiodinase activity in critically ill patients.
Methods: Serum thyroid hormones and IL-1β were measured on the 5th, 15th, and last day of 80 critically ill patients. Forty of these patients were non-survived, and liver and skeletal muscle were harvested to analyze deiodinase activity.
Results: Serum TSH, T4, and T3 were decreased, and rT3 and IL-1β were increased in non-survivors. From day 5 to the last day, serum TSH, T4, and T3 levels increased, and rT3 and IL-1β levels decreased with time in survivors, while serum TSH, T4, and T3 levels decreased or remained unchanged, and rT3 and IL-1β increased in non-survivors. On the last day, liver D1 activity was in a negative correlation with serum rT3 and IL-1β, while liver and skeletal muscle D3 activities were in a positive correlation.
Conclusion: Serum thyroid hormones and IL-1β are correlated with postmortem deiodinase activity in critically ill patients.
References
1. Van den Berghe G: Dynamic neuroendocrine responses to critical illness. Frontiers in neuroendocrinology 2002, 23(4):370-391.
2. Ligtenberg J, Girbes A, Beentjes J, Tulleken J, van der Werf T, Zijlstra J: Hormones in the critically ill patient: to intervene or not to intervene? Intensive care medicine 2001, 27(10):1567-1577.
3. Van den Berghe G, Baxter R, Weekers F, Wouters P, Bowers C, Iranmanesh A, Veldhuis J, Bouillon R: The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clinical endocrinology 2002, 56(5):655-669.
4. Takala J, Ruokonen E, Webster N, Nielsen M, Zandstra D, Vundelinckx G, Hinds C: Increased mortality associated with growth hormone treatment in critically ill adults. The New England journal of medicine 1999, 341(11):785-792.
5. Bone R, Fisher C, Clemmer T, Slotman G, Metz C, Balk R: A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. The New England journal of medicine 1987, 317(11):653-658.
6. Slotman G, Fisher C, Bone R, Clemmer T, Metz C: Detrimental effects of high-dose methylprednisolone sodium succinate on serum concentrations of hepatic and renal function indicators in severe sepsis and septic shock. The Methylprednisolone Severe Sepsis Study Group. Critical care medicine 1993, 21(2):191-195.
7. Brent G, Hershman J: Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentration. The Journal of clinical endocrinology and metabolism 1986, 63(1):1-8.
8. Van den Berghe G: Growth hormone secretagogues in critical illness. Hormone research 1999:21-28.
9. Docter R, Krenning E, de Jong M, Hennemann G: The sick euthyroid syndrome: changes in thyroid hormone serum parameters and hormone metabolism. Clinical endocrinology 1993, 39(5):499-518.
10. Bianco A, Salvatore D, Gereben B, Berry M, Larsen P: Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocrine reviews 2002, 23(1):38-89.
11. Cicatiello A, Di Girolamo D, Dentice M: Metabolic Effects of the Intracellular Regulation of Thyroid Hormone: Old Players, New Concepts. Frontiers in endocrinology 2018, 9:474.
12. Kaptein E, Robinson W, Grieb D, Nicoloff J: Peripheral serum thyroxine, triiodothyronine and reverse triiodothyronine kinetics in the low thyroxine state of acute nonthyroidal illnesses. A noncompartmental analysis. The Journal of clinical investigation 1982, 69(3):526-535.
13. Faber J, Thomsen H, Lumholtz I, Kirkegaard C, Siersbaek-Nielsen K, Friis T: Kinetic studies of thyroxine, 3,5,3'-triiodothyronine, 3,3,5'-triiodothyronine, 3',5'-diiodothyronine, 3,3'-diiodothyronine, and 3'-monoiodothyronine in patients with liver cirrhosis. The Journal of clinical endocrinology and metabolism 1981, 53(5):978-984.
14. Kaptein E, Feinstein E, Nicoloff J, Massry S: Serum reverse triiodothyronine and thyroxine kinetics in patients with chronic renal failure. The Journal of clinical endocrinology and metabolism 1983, 57(1):181-189.
15. Hennemann G, Docter R, Friesema E, de Jong M, Krenning E, Visser T: Plasma membrane transport of thyroid hormones and its role in thyroid hormone metabolism and bioavailability. Endocrine reviews 2001, 22(4):451-476.
16. Huang S, Tu H, Harney J, Venihaki M, Butte A, Kozakewich H, Fishman S, Larsen P: Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. The New England journal of medicine 2000, 343(3):185-189.
17. Yan Y, Jin P, Lu J, Cheng D, Xu J, Yuan J, Yu Z, Hu Y: Postoperative cytokine levels and their predictive value in critical patients after major abdominal surgery: a retrospective cohort study. Annals of palliative medicine 2022, 11(1):1-15.
18. Guo Q, Wu Y, Hou Y, Liu Y, Liu T, Zhang H, Fan C, Guan H, Li Y, Shan Z et al: Cytokine Secretion and Pyroptosis of Thyroid Follicular Cells Mediated by Enhanced NLRP3, NLRP1, NLRC4, and AIM2 Inflammasomes Are Associated With Autoimmune Thyroiditis. Frontiers in immunology 2018, 9:1197.
19. Zhang Q, Ye X, Zhou Z, Zhu C, Li R, Fang Y, Zhang R, Li L, Liu W, Wang Z et al: Lymphocyte infiltration and thyrocyte destruction are driven by stromal and immune cell components in Hashimoto's thyroiditis. Nature communications 2022, 13(1):775.
20. Cao Y, Sun Y, Jin X, Li X, Chen L, Qiu Y: TIM4/NLRP3 axis participates in the effects of M1 macrophages on inflammatory factor release, apoptosis and cell adhesion in thyroid follicular cells. Experimental and therapeutic medicine 2022, 24(5):679.
21. Zhao R, Zhou H, Su S: A critical role for interleukin-1β in the progression of autoimmune diseases. International immunopharmacology 2013, 17(3):658-669.
22. Rebuffat S, Kammoun-Krichen M, Charfeddine I, Ayadi H, Bougacha-Elleuch N, Peraldi-Roux S: IL-1β and TSH disturb thyroid epithelium integrity in autoimmune thyroid diseases. Immunobiology 2013, 218(3):285-291.
23. Mendel CM, Frost PH, Kunitake ST, Cavalieri RR: Mechanism of the heparin-induced increase in the concentration of free thyroxine in plasma. J Clin Endocrinol Metab 1987, 65(6):1259-1264.
24. Visser TJ, Docter R, Hennemann G: Radioimmunoassay of reverse tri-iodothyronine. J Endocrinol 1977, 73(2):395-396.
25. Peeters RP, Wouters PJ, Kaptein E, van Toor H, Visser TJ, Van den Berghe G: Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. J Clin Endocrinol Metab 2003, 88(7):3202-3211.
26. McIver B, Gorman C: Euthyroid sick syndrome: an overview. Thyroid : official journal of the American Thyroid Association 1997, 7(1):125-132.
27. Kaptein E, Weiner J, Robinson W, Wheeler W, Nicoloff J: Relationship of altered thyroid hormone indices to survival in nonthyroidal illnesses. Clinical endocrinology 1982, 16(6):565-574.
28. Slag M, Morley J, Elson M, Crowson T, Nuttall F, Shafer R: Hypothyroxinemia in critically ill patients as a predictor of high mortality. JAMA 1981, 245(1):43-45.
29. Hamblin P, Dyer S, Mohr V, Le Grand B, Lim C, Tuxen D, Topliss D, Stockigt J: Relationship between thyrotropin and thyroxine changes during recovery from severe hypothyroxinemia of critical illness. The Journal of clinical endocrinology and metabolism 1986, 62(4):717-722.
30. Bacci V, Schussler G, Kaplan T: The relationship between serum triiodothyronine and thyrotropin during systemic illness. The Journal of clinical endocrinology and metabolism 1982, 54(6):1229-1235.
31. LoPresti J, Eigen A, Kaptein E, Anderson K, Spencer C, Nicoloff J: Alterations in 3,3'5'-triiodothyronine metabolism in response to propylthiouracil, dexamethasone, and thyroxine administration in man. The Journal of clinical investigation 1989, 84(5):1650-1656.
32. LoPresti J, Gray D, Nicoloff J: Influence of fasting and refeeding on 3,3',5'-triiodothyronine metabolism in man. The Journal of clinical endocrinology and metabolism 1991, 72(1):130-136.
33. Richard K, Hume R, Kaptein E, Sanders J, van Toor H, De Herder W, den Hollander J, Krenning E, Visser T: Ontogeny of iodothyronine deiodinases in human liver. The Journal of clinical endocrinology and metabolism 1998, 83(8):2868-2874.
34. Kester M, Kaptein E, Van Dijk C, Roest T, Tibboel D, Coughtrie M, Visser T: Characterization of iodothyronine sulfatase activities in human and rat liver and placenta. Endocrinology 2002, 143(3):814-819.
35. Peeters R, Wouters P, Kaptein E, van Toor H, Visser T, Van den Berghe G: Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. The Journal of clinical endocrinology and metabolism 2003, 88(7):3202-3211.
36. Salvatore D, Bartha T, Harney J, Larsen P: Molecular biological and biochemical characterization of the human type 2 selenodeiodinase. Endocrinology 1996, 137(8):3308-3315.
37. Steinsapir J, Bianco A, Buettner C, Harney J, Larsen P: Substrate-induced down-regulation of human type 2 deiodinase (hD2) is mediated through proteasomal degradation and requires interaction with the enzyme's active center. Endocrinology 2000, 141(3):1127-1135.
38. Peeters R, van den Beld A, Attalki H, Toor H, de Rijke Y, Kuiper G, Lamberts S, Janssen J, Uitterlinden A, Visser T: A new polymorphism in the type II deiodinase gene is associated with circulating thyroid hormone parameters. American journal of physiology Endocrinology and metabolism 2005, 289(1):E75-81.
39. Zaher S, Branco R, Meyer R, White D, Ridout J, Pathan N: Relationship between inflammation and metabolic regulation of energy expenditure by GLP-1 in critically ill children. Clinical nutrition (Edinburgh, Scotland) 2021, 40(2):632-637.
40. Kurimoto C, Inaba H, Ariyasu H, Iwakura H, Ueda Y, Uraki S, Takeshima K, Furukawa Y, Morita S, Yamamoto Y et al: Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors. Cancer science 2020, 111(5):1468-1477.
Copyright (c) 2024 ZhenZhou Zhong, XiaoLiu Xiao
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.